Kymera Therapeutics (KYMR) announced that it will host a video webcast on Friday, May 9, 2025. The company will report first quarter 2025 financial results and also disclose its new oral development candidate targeting a high value undrugged target for multiple autoimmune and rheumatic diseases. Additionally, the Company will review highlights and upcoming milestones across its industry-leading immunology pipeline.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics announces first patient dosed in BROADEN Phase 1b trial
- Kymera Therapeutics appoints Goodman as Chief Business Officer
- Cautious Hold Rating on Kymera Therapeutics Amid Promising KT-621 Prospects and Strategic Developments
- Kymera Therapeutics initiated with a Buy at Citi
- Kymera Therapeutics: Leading the Way with Innovative STAT6 Degrader KT-621